DBV Technologies stock rebounds following filing of peanut allergy patch with the FDA
The Châtillon-based biotech is among the best performers of the SBF 120 mid-morning, bucking a slightly red index. The announcement of the submission of a biologics license application to the FDA for its peanut allergy patch breathes new life into a stock that was still down 13.65% over one month.
FDA request for peanut patch relaunches stock momentum
DBV Technologies filed on Wednesday a biologics license application (BLA) with the FDA for its peanut allergy patch, intended for children aged 4 to 7 years, requesting priority review of the file. This BLA submission represents the most advanced regulatory milestone ever reached by the company in the United States and fulfills the guidance communicated when the company published its first-half 2026 results on July 16, which anticipated this submission in the third quarter of 2026. The biotech, which has not yet generated commercial revenues and has an announced financing horizon through the third quarter of 2027, now places its fate in the hands of the American regulator. The stock gains 1.59% to €2.05 during the session, after closing the previous day at €2.018, near the €2.00 support level.
A fragile technical rebound in the face of sharply rising short positions
Despite this uptick, the chart configuration of DBV Technologies remains deteriorated. The price is trading below its three moving averages: the 20-day MA at €2.18, the 50-day MA at €2.33, and the 200-day MA at €3.11, the latter representing a gap of more than 34%. The RSI at 37 is approaching the oversold zone without reaching it clearly, reflecting a selling exhaustion that could be temporarily interrupted by today's announcement. Over one year, the stock is still up 29.75%, a sign that the security has gone through phases of euphoria before declining since summer.
The context of selling pressure remains structural: according to recorded declarations, four funds account for 4.30% of the capital sold short, up 0.91 percentage points over thirty days, compared to 3.39% a month ago. This elevated level signals that institutional investors remain positioned against the value, which could limit the amplitude of a rebound even in the presence of good regulatory news. The next step depends on the FDA's decision on the acceptance and examination timeline of the file.
